Abstract: The present invention provides a recombinant strain highly producing fibrinogen which is an animal cell strain coexpressing a fibrinogen and an ?2PI and/or PAI-2, genes encoding A? chain, B? chain and ? chain of fibrinogen, a production method of a recombinant strain highly producing fibrinogen, including introducing gene(s) encoding ?2PI and/or PAI-2 into an animal cell, and coexpressing fibrinogen and ?2PI and/or PAI-2 in the animal cell, and a production method of a recombinant fibrinogen including culturing a recombinant strain highly producing fibrinogen in a medium, and recovering fibrinogen from the obtained culture.

Abstract: The present invention provides a recombinant strain highly producing fibrinogen which is an animal cell strain coexpressing a fibrinogen and an ?2PI and/or PAI-2, genes encoding A? chain, B? chain and ? chain of fibrinogen, a production method of a recombinant strain highly producing fibrinogen, including introducing gene(s) encoding ?2PI and/or PAI-2 into an animal cell, and coexpressing fibrinogen and ?2PI and/or PAI-2 in the animal cell, and a production method of a recombinant fibrinogen including culturing a recombinant strain highly producing fibrinogen in a medium, and recovering fibrinogen from the obtained culture.

Abstract: According to the present invention, it is possible to provide a novel cell penetrating peptide that transports proteins into cells and/or into nuclei at higher frequency than conventional cell penetrating peptides, and a pharmaceutical containing the peptide.

Abstract: According to the present invention, it is possible to provide a novel cell penetrating peptide that transports proteins into cells and/or into nuclei at higher frequency than conventional cell penetrating peptides, and a pharmaceutical containing the peptide.

Abstract: According to the present invention, it is possible to provide a novel cell penetrating peptide that transports proteins into cells and/or into nuclei at higher frequency than conventional cell penetrating peptides, and a pharmaceutical containing the peptide.

Abstract: According to the present invention, it is possible to provide a novel cell penetrating peptide that transports proteins into cells and/or into nuclei at higher frequency than conventional cell penetrating peptides, and a pharmaceutical containing the peptide.

Abstract: A cell death inducer for mast cells, a preventive/therapeutic agent for diseases in which mast cells are implicated, having a fusion protein including a PTD and an MITF variant as an active ingredient and a fusion protein comprises a His Tag, a PTD, and an MITF variant, wherein the MITF variant being an MITF mi variant, wh variant, HLH fragment, or A-type N-terminal region (1-305) fragment, and the PTD being a TAT-derived peptide; DNA coding for the fusion protein; and a method for preparing the fusion protein using genetic engineering techniques. Actions of the fusion protein of the present invention include inhibiting an activity of endogenous MITF by translocating into mast cells, inhibiting a survival of mast cells derived from precursor cells, and inducing cell death (apoptosis) in mature mast cells.

Abstract: A cell death inducer for mast cells, a preventive/therapeutic agent for diseases in which mast cells are implicated, having a fusion protein including a PTD and an MITF variant as an active ingredient and a fusion protein comprises a His Tag, a PTD, and an MITF variant, wherein the MITF variant being an MITF mi variant, wh variant, HLH fragment, or A-type N-terminal region (1-305) fragment, and the PTD being a TAT-derived peptide; DNA coding for the fusion protein; and a method for preparing the fusion protein using genetic engineering techniques. Actions of the fusion protein of the present invention include inhibiting an activity of endogenous MITF by translocating into mast cells, inhibiting a survival of mast cells derived from precursor cells, and inducing cell death (apoptosis) in mature mast cells.

Abstract: It is the matter to be solved by the present invention to provide mRNA coding for the PGT of a human brain type and to provide a polynucleotide coding for the PGT of a human brain type prepared using the said mRNA as a template. There are provided mRNA coding for the PGT of a human brain type and having a molecular weight of 38-40 kilodaltons and a polynucleotide being prepared by the use of the said mRNA as a template and having a specific base sequence represented by SEQ ID NO: 2 of the Sequence Listing.

Abstract: A mutant AOX2 promoter obtained by mutating a sequence of natural AOX2 promoter in a manner comprising at least one of the three mutation modes of (1) a region extending upstream from nucleotide 1187 inclusive and comprising at least nucleotides 845-960 is deleted, (2) nucleotide(s) is(are) replaced in region(s) in nucleotides 1274-1314, and (3) new oligonucleotide(s) is (are) inserted in region(s) in nucleotides 1274-1314, a vector carrying said mutant AOX2 promoter, a transformant into which said vector has been introduced, and a method for producing a heterologous protein, which comprises cultivating said transformant. The promoter of the present invention has remarkably enhanced activity as compared with natural AOX2 promoter, and is highly useful as a promoter to be carried in an expression vector allowing heterologous protein expression. In addition, the vector and the transformant of the invention can efficiently express and produce various useful heterologous proteins.

Abstract: A human prourokinase mutant in which the entire or a partial epidermal growth factor domain of human prourokinase is deleted or a partial epidermal growth factor domain of human prourokinase is replaced by one or more different amino acid residues, said mutant having a longer blood half-life than naturally occurring human prourokinase while retaining prourokinase enzymatic activity. In this human prourokinase mutant the region selected from the group consisting of: (a) from asparagine (10) to cysteine (42); (b) from asparagine (10) to aspartic acid (45); and (c) from asparagine (10) to threonine (49) is missing.